Table 1.
Summary of HCV Prevalence Studies Across the Mena Countries, That Were Included in Analysis, Stratified by Population Epidemiologic Category
| Population | Number of HCV Prevalence Measures | Number of Individuals Tested for HCV | Number of HCV Antibody‐Positive Individuals |
|---|---|---|---|
| People who inject drugs | 108 | 44,094 | 17,004 |
| Populations with high‐risk health care exposures | 440 | 123,249 | 45,034 |
| Populations at intermediate risk | 340 | 290,721 | 31,204 |
| General populations | 1,182 | 48,245,780 | 299,489 |
| Populations with liver conditions | 245 | 131,343 | 51,069 |
| Special clinical populations | 206 | 96,592 | 15,798 |
| All populations | 2,521 | 48,931,779 | 459,598 |